Delays in oncologic care for newly diagnosed thoracic malignancies: A quality improvement analysis at a single institution.
Abstract
551 Background: Patients with newly diagnosed thoracic malignancies frequently experience delays in diagnosis and treatment initiation, particularly during transitions from inpatient to outpatient oncologic care. Geographic barriers and limited access to specialty services may contribute to treatment delays. We performed a retrospective quality improvement analysis to identify factors associated with delayed oncologic care at a single institution in Mobile, Alabama. Methods: We conducted a retrospective quality improvement analysis of adult patients with newly diagnosed thoracic malignancies presenting through either the emergency department (ED) or outpatient setting at a tertiary referral center between 2024 and 2025. Time intervals evaluated included imaging-to-biopsy, presentation-to-diagnosis, biopsy-to-oncology consultation, presentation-to-oncology evaluation, and biopsy-to-treatment initiation. Median and mean time intervals were calculated. Subgroup analyses were performed based on disease stage, insurance status, patient location, and presentation setting using nonparametric testing. Results: A total of 49 patients were included. Median time from imaging to biopsy and presentation to diagnosis was 20 days each. Median time from biopsy to first oncology consultation was 19 days, while median time from presentation to oncology evaluation was 46 days. Median time from biopsy to treatment initiation was 57 days. Mean time intervals were substantially longer across all categories, including imaging-to-biopsy (48.9 days), presentation-to-diagnosis (48.8 days), biopsy-to-oncology consultation (37.2 days), presentation-to-oncology evaluation (85.3 days), and biopsy-to-treatment initiation (79.4 days), suggesting delays in a subset of patients. Outpatient presentation was associated with longer median time from biopsy to oncology consultation compared with ED presentation (35 vs 16 days, p=0.015). Insurance status was significantly associated with biopsy-to-treatment initiation, with privately insured patients demonstrating the longest median delays compared with Medicare and Medicaid/self-pay groups (80 vs 37 vs 43 days, p=0.029). Patients residing outside the primary referral region demonstrated a trend toward longer treatment delays (68 vs 46 days, p=0.091). Stage was not associated with treatment delay. Conclusions: Patients with newly diagnosed thoracic malignancies experienced prolonged delays throughout the oncologic care pathway, particularly between tissue diagnosis and treatment initiation. Geographic and insurance-related factors may contribute to delayed treatment initiation. Future quality improvement efforts will focus on improving oncology referral pathways and transition-of-care coordination while expanding this analysis to other malignancies, including gastrointestinal cancers.